Trastuzumab (Dutch Wikipedia)

Analysis of information sources in references of the Wikipedia article "Trastuzumab" in Dutch language version.

refsWebsite

Global rank Dutch rank

2^nd place

8^th place

low place

887^th place

5^th place

28^th place

447^th place

1,002^nd place

1geneesmiddeleninformatiebank.nl

low place

1,934^th place

low place

2,353^rd place

68^th place

39^th place

1web.archive.org

1^st place

1^st place

1farmacotherapeutischkompas.nl

low place

186^th place

4^th place

12^th place

apotheek.nl

Apotheek.nl. www.apotheek.nl. Geraadpleegd op 5 juni 2023.
https://www.apotheek.nl/medicijnen/trastuzumab#wat-zijn-mogelijke-bijwerkingen

bcfi.be

https://www.bcfi.be/nl/chapters/14?frag=13201&trade_family=12260

doi.org

dx.doi.org

(en) Heo, Young-A, Syed, Yahiya Y. (1 december 2019). Subcutaneous Trastuzumab: A Review in HER2-Positive Breast Cancer. Targeted Oncology 14 (6): 749–758. ISSN:1776-260X. DOI:10.1007/s11523-019-00684-y.
Denys, Hannelore, Martinez-Mena, Corina L., Martens, Marc T., D'Hondt, Randal G., Graas, Marie-Pascale L. (2020-05). Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer. Breast Cancer Research and Treatment 181 (1): 97–105. ISSN:1573-7217. PMID: 32240454. PMC: 7182624. DOI:10.1007/s10549-020-05604-7.

doi.org

(en) Heo, Young-A, Syed, Yahiya Y. (1 december 2019). Subcutaneous Trastuzumab: A Review in HER2-Positive Breast Cancer. Targeted Oncology 14 (6): 749–758. ISSN:1776-260X. DOI:10.1007/s11523-019-00684-y.

europa.eu

ema.europa.eu

(en) EMA, Herceptin. European Medicines Agency (17 september 2018). Geraadpleegd op 5 juni 2023.

farmacotherapeutischkompas.nl

https://www.farmacotherapeutischkompas.nl/bladeren/preparaatteksten/t/trastuzumab#advies

fda.gov

(en) Office of the Commissioner, FDA approves first biosimilar for the treatment of certain breast and stomach cancers. FDA (24 maart 2020). Geraadpleegd op 5 juni 2023.

geneesmiddeleninformatiebank.nl

Geneesmiddelen, College ter Beoordeling van, Geneesmiddeleninformatiebank - College ter Beoordeling van Geneesmiddelen. www.geneesmiddeleninformatiebank.nl (22 december 2014). Geraadpleegd op 5 juni 2023.

nih.gov

ncbi.nlm.nih.gov

Denys, Hannelore, Martinez-Mena, Corina L., Martens, Marc T., D'Hondt, Randal G., Graas, Marie-Pascale L. (2020-05). Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer. Breast Cancer Research and Treatment 181 (1): 97–105. ISSN:1573-7217. PMID: 32240454. PMC: 7182624. DOI:10.1007/s10549-020-05604-7.

web.archive.org

Trastuzumab Product Approval Information - Licensing Action 9/25/98. web.archive.org (28 januari 2017). Gearchiveerd op 28 januari 2017. Geraadpleegd op 5 juni 2023.

worldcat.org

(en) Heo, Young-A, Syed, Yahiya Y. (1 december 2019). Subcutaneous Trastuzumab: A Review in HER2-Positive Breast Cancer. Targeted Oncology 14 (6): 749–758. ISSN:1776-260X. DOI:10.1007/s11523-019-00684-y.
Denys, Hannelore, Martinez-Mena, Corina L., Martens, Marc T., D'Hondt, Randal G., Graas, Marie-Pascale L. (2020-05). Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer. Breast Cancer Research and Treatment 181 (1): 97–105. ISSN:1573-7217. PMID: 32240454. PMC: 7182624. DOI:10.1007/s10549-020-05604-7.